Patents by Inventor Gary Brian Evans

Gary Brian Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of helicobacter pylori infections
    Patent number: 11186575
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering to the subject an inhibitor of H.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 30, 2021
    Assignees: Alber Einslein College of Medicine, Victoria Link Limited
    Inventors: Vern L. Schramm, Shanzhi Wang, Antti Marko Haapalainen, Gary Brian Evans, Richard Hubert Furneaux, Keith Clinch, Peter Charles Tyler, Shivali Ashwin Gulab
  • Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)
    Patent number: 10227351
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: March 12, 2019
    Assignee: Victoria Link Limited
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2,-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRODIN-3-OL(MTDIA)
    Publication number: 20180319803
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Application
    Filed: May 31, 2018
    Publication date: November 8, 2018
    Applicant: VICTORIA LINK LIMITED
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)
    Patent number: 9994574
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 12, 2018
    Assignee: Victoria Link Limited
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • 3-hydroxypyrrolidine inhibitors of 5?-methylthioadenosine phosphorylase and nucleosidase
    Patent number: 9957272
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 1, 2018
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine, Inc.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
    Publication number: 20170166573
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to in 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: November 10, 2016
    Publication date: June 15, 2017
    Applicants: VICTORIA LINK LIMITED, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • 3-hydroxypyrrolidine inhibitors of 5?-methylthioadenosine phosphorylase and nucleosidase
    Patent number: 9493465
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 15, 2016
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine, Inc.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
    Patent number: 9290501
    Abstract: The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5?-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 22, 2016
    Assignees: Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Vern L. Schramm, Keith Clinch, Peter Charles Tyler, Gary Brian Evans, Richard Hubert Furneaux
  • SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2,-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRODIN-3-OL(MTDIA)
    Publication number: 20150274741
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Application
    Filed: November 12, 2013
    Publication date: October 1, 2015
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • TREATMENT OF HELICOBACTER PYLORI INFECTIONS
    Publication number: 20150210701
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
    Type: Application
    Filed: August 7, 2013
    Publication date: July 30, 2015
    Applicants: ALBERTEINSTIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, CALLAGHAN INNOVATION RESEARCH LIMITED
    Inventors: Vern L. Schramm, Shanzhi Wang, Antti Marko Haapalainen, Gary Brian Evans, Richard Hubert Furneaux, Keith Clinch, Peter Charles Tyler, Shivali Ashwin Gulab
  • Saporin-L1 inhibitors and uses thereof
    Patent number: 8884000
    Abstract: Inhibitors of saporin-L1 are disclosed, as are related compositions and uses thereof, in particular in cancer therapy that employs saporin-L1-linked immunotoxins.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: November 11, 2014
    Assignees: Albert Einstein College of Medicine of Yeshiva University, Industrial Research Limited
    Inventors: Vern L. Schramm, Gary Brian Evans, Peter Charles Tyler, Jennifer Mary Mason
  • Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
    Patent number: 8853224
    Abstract: The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: October 7, 2014
    Assignees: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Keith Clinch, Gary Brian Evans, Richard Hubert Furneaux, Shivali Ashwin Gulab, Peter Michael Kelly, Vern L. Schramm, Peter Charles Tyler, Anthony David Woolhouse
  • METHODS, ASSAYS AND COMPOUNDS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING METHYLTHIOINOSINE PHOSPHORYLASE
    Publication number: 20130274220
    Abstract: The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5?-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.
    Type: Application
    Filed: November 28, 2011
    Publication date: October 17, 2013
    Applicants: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Vern L. Schramm, Keith Clinch, Peter Charles Tyler, Gary Brian Evans, Richard Hubert Furneaux
  • Analogues of coformycin and their use for treating protozoan parasite infections
    Patent number: 8394950
    Abstract: This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: March 12, 2013
    Assignees: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Richard Hubert Furneaux, Peter Charles Tyler, Gary Brian Evans, Vern L. Schramm, Kami Kim, Richard Fröhlich
  • Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
    Patent number: 8383636
    Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 26, 2013
    Assignees: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Keith Clinch, Gary Brian Evans, Richard Frohlich, Richard Hubert Furneaux, Peter Michael Kelly, Jennifer Mary Mason, Vern L. Schramm, Peter Charles Tyler, Shivall Ashwah Ashwin Gulab
  • Azetidine analogues of nucleosidase and phosphorylase inhibitors
    Patent number: 8283345
    Abstract: Disclosed are azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: October 9, 2012
    Assignees: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Gary Brian Evans, Richard Hubert Furneaux, Ben William Greatrex, Vern L. Schramm, Peter Charles Tyler
  • 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
    Publication number: 20120157479
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: July 16, 2010
    Publication date: June 21, 2012
    Applicants: INDUSTRIAL RESEARCH LIMITED, ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
    Patent number: 8183019
    Abstract: A process is disclosed for preparing (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (I), or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (Ia) involving, as a key step, the enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone compound of formula (II).
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: May 22, 2012
    Assignee: Industrial Research Limited
    Inventors: Dirk Henning Lenz, Jennifer Mary Mason, Keith Clinch, Gary Brian Evans, Peter Charles Tyler
  • Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases
    Patent number: 8173662
    Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5?-methylthioadenosine phosphorylases (MTAP), 5?-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: May 8, 2012
    Assignees: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Gary Brian Evans, Richard Hubert Furneaux, Dirk Henning Lenz, Vern L. Schramm, Peter Charles Tyler, Olga Vladimirovna Zubkova
  • Saporin-L1 inhibitors and uses thereof
    Publication number: 20110201674
    Abstract: Inhibitors of saporin-L1 are disclosed, as are related compositions and uses thereof, in particular in cancer therapy that employs saporin-L1-linked immunotoxins.
    Type: Application
    Filed: February 15, 2011
    Publication date: August 18, 2011
    Inventors: Vern L. Schramm, Gary Brian Evans, Peter Charles Tyler, Jennifer Mary Mason